Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium + lactobacillus casei M8
- Development stage
- Unknown
- Lead developer
- Weihai Municipal Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
bifidobacterium + lactobacillus casei M8 is a probiotic combination therapy being evaluated for the treatment of high-risk human papillomavirus (HPV) infection and cervical intraepithelial neoplasia (CIN). Developed in research contexts such as those at Weihai Municipal Hospital, the therapy utilizes the specific probiotic strain Lactobacillus casei M8 alongside Bifidobacterium species. The mechanism of action involves the restoration of a healthy vaginal microbiota, which is typically dominated by Lactobacillus species. By re-establishing microbial balance, the treatment aims to create an environment inhospitable to HPV persistence, enhance local mucosal immunity, and promote the clearance of viral infections, thereby preventing the progression of CIN to cervical cancer.
- Other names
- Bifidobacterium + Lactobacillus casei M8Lactobacillus casei M8 + Bifidobacterium
Beyond the preview
Go deeper on bifidobacterium + lactobacillus casei M8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium + lactobacillus casei M8.